Merkel cell carcinomas (MCC) belong to the family of neuroendocrine tumors. In addition to other markers, they express somatostatin receptors. They are uncommon, highly malignant skin tumors with an aggressive clinical course. They develop in sun-exposed areas of the skin, mostly in elderly patients. In addition to frequent locoregional recurrences, there is a high incidence of distant metastases. Treatment is stage dependent and consists of operation and chemo- and/or radiotherapy, respectively. The advanced age of patients often impedes adequate therapy. 90Y-DOTATOC is a novel radiolabeled somatostatin analogue containing the active octapeptide of somatostatin. It is very well tolerated and offers the option of treating somatostatin receptor-positive tumors by targeted radiotherapy. We report the case of an 83-year-old woman with recurrent MCC of the left cheek. The primary tumor and several relapses were treated with surgery and locoregional radiotherapy. After the 3rd relapse, she was treated 4 times with 90Y-DOTATOC and two complete remissions were achieved. The fourth administration after the 2nd relapse was ineffective and conventional chemotherapy was started. There were no side effects of the 90Y-DOTATOC. We conclude that due to its good tolerability, 90Y-DOTATOC therapy should be evaluated further as a new therapy for somatostatin receptor-positive MCC.

Keywords:
Merkel cell carcinoma, 90Y-DOTATOC, Somatostatin, Neuroendocrine tumor, Skin neoplasms
1.
Toker C: Trabecular carcinoma of the skin. Arch Dermatol 1972;105:107–110.
2.
Schmidt U, Muller U, Metz KA, Leder LD: Cytokeratin and neurofilament protein staining in Merkel cell carcinoma of the small cell type and small cell carcinoma of the lung. Am J Dermatopathol 1998;20:346–351.
3.
Hitchcock CL, Bland KI, Laney RG, Franzini D, Harris B, Copeland EM: Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment. Ann Surg 1988;207:201–207.
4.
Gollard R, Weber R, Kosty MP, Greenway HAT, Massullo V, Humberson C: Merkel cell carcinoma: Review of 22 cases with surgical, pathologic, and therapeutic considerations. Cancer 2000;88:1842–1851.
5.
Penn I, First MR: Merkel’s cell carcinoma in organ recipients: Report of 41 cases. Transplantation 1999;68:1717–1721.
6.
Brenner B, Sulkes A, Rakowsky E, Feinmesser M, Yukelson A, Bar-Haim E, Katz A, Idelevich E, Neuman A, Barhana M, Fenig E: Second neoplasms in patients with Merkel cell carcinoma. Cancer 2001;91:1358–1362.
7.
Allen PJ, Zhang ZF, Coit DG: Surgical management of Merkel cell carcinoma. Ann Surg 1999;229:97–105.
8.
Voog E, Biron P, Martin JP, Blay JY: Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 1999;85:2589–2595.
9.
Ott MJ, Tanabe KK, Gadd MA, Stark P, Smith BL, Finkelstein DM, Souba WW: Multimodality management of Merkel cell carcinoma. Arch Surg 1999;134:388–393.
10.
O’Connor WJ, Roenigk RK, Brodland DG: Merkel cell carcinoma. Comparison of Mohs micrographic surgery and wide excision in eighty-six patients. Dermatol Surg 1997;23:929–933.
11.
Lawenda BD, Thiringer JK, Foss RD, Johnstone PA: Merkel cell carcinoma arising in the head and neck: Optimizing therapy. Am J Clin Oncol 2001;24:35–42.
12.
Allen PJ, Busam K, Hill AD, Stojadinovic A, Coit DG: Immunohistochemical analysis of sentinel lymph nodes from patients with Merkel cell carcinoma. Cancer 2001;92:1650–1655.
13.
Duker I, Starz H, Bachter D, Balda BR: Prognostic and therapeutic implications of sentinel lymphonodectomy and S-staging in Merkel cell carcinoma. Dermatology 2001;202:225–229.
14.
Hill AD, Brady MS, Coit DG: Intraoperative lymphatic mapping and sentinel lymph node biopsy for Merkel cell carcinoma. Br J Surg 1999;86:518–521.
15.
Linjawi A, Jamison WB, Meterissian S: Merkel cell carcinoma: Important aspects of diagnosis and management. Am Surg 2001;67:943–947.
16.
Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI, Beenken SW: Multimodality treatment of Merkel cell carcinoma: Case series and literature review of 1,024 cases. Ann Surg Oncol 2001;8:204–208.
17.
Kokoska ER, Kokoska MS, Collins BT, Stapleton DR, Wade TP: Early aggressive treatment for Merkel cell carcinoma improves outcome. Am J Surg 1997;174:688–693.
18.
Savage P, Constenla D, Fisher C, Thomas JM, Gore ME: The natural history and management of Merkel cell carcinoma of the skin: A review of 22 patients treated at the Royal Marsden Hospital. Clin Oncol (R Coll Radiol) 1997;9:164–167.
19.
Fenig E, Brenner B, Katz A, Rakovsky E, Hana MB, Sulkes A: The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. Cancer 1997;80:881–885.
20.
Wilder RB, Harari PM, Graham AR, Shimm DS, Cassady JR: Merkel cell carcinoma. Improved locoregional control with postoperative radiation therapy. Cancer 1991;68:1004–1008.
21.
Gillenwater AM, Hessel AC, Morrison WH, Burgess M, Silva EG, Roberts D, Goepfert H: Merkel cell carcinoma of the head and neck: Effect of surgical excision and radiation on recurrence and survival. Arch Otolaryngol Head Neck Surg 2001;127:149–154.
22.
Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, Gilchrist J: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: Case series and review of 204 cases. J Clin Oncol 2000;18:2493–2499.
23.
Guitera-Rovel P, Lumbroso J, Gautier-Gougis MS, Spatz A, Mercier S, Margulis S, Mamelle G, Kolb F, Lartigau E, Avril MF: Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases. Ann Oncol 2001;12:807–811.
24.
Maecke HR, Béhé M, Froidevaux S: DOTA- D-Phe(1)-Tyr(3)-octreotide (DOTATOC): A unique somatostatin receptor ligand for labeling with a variety of metallic radionuclides. J Nucl Med 1997;38:18P.
25.
Béhé M, Heppeler A, Maecke HR: New somatostatin analogs for SPET and PET (abstract). Eur J Nucl Med 1996;23:1144.
26.
Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR: Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417–418.
27.
Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J: Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439–1447.
28.
Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J: The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 2001;12:941–945.
29.
Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU, Haldemann A, Mueller-Brand J: Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octreotide: A pilot study. Nucl Med Commun 2001;22:673–678.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.